• 1
    Thames HD, Hendry JH. Fractionation in radiotherapy. New York: Taylor & Francis, 1987:234.
  • 2
    Hall EJ. Radiation biology. Cancer 1985; 55: 20517.
  • 3
    Fu KK, Pajak TF, Trotti A, Jones CU, Spencer SA, Phillips TL, et al. A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinoas: First report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000; 48: 716.
  • 4
    Fu KK, Withers HR, Peters LJ. Transmutability of dose and time commentary on the first report of RTOG 90003. Int J Radiat Oncol Biol Phys 2000; 48: 12.
  • 5
    Fowler JF, Harari PM. Confirmation of improved local-regional control with altered fractionation in head and neck cancer. Int J Radiat Oncol Biol Phys 2000; 48: 36.
  • 6
    Fischer JJ, Moulder JE. The steepness of the dose-response curve in radiation therapy. Radiology 1975; 117: 17984.
  • 7
    Kroger LA, DeNardo GL, Gumerlock PH, Xiong CY, Winthrop MD, Shi XB, et al. Apoptosis related gene and protein expression in human lymphoma xenografts (Raji) after low dose rate radiation using 67Cu-2IT-BAT-Lym-1 radioimmunotherapy. Cancer Biother Radiopharm 2001; 16: 24762.
  • 8
    Knox SJ, Goris ML, Wessels BW. Overview of animal studies comparing radioimmunotherapy with dose equivalent external beam irradiation. Radiother Oncol 1992; 23: 1117.
  • 9
    Wessels BW, Vessella RL, Palme DF, Berkopec JM, Smith GK, Bradley EW. Radiobiological comparison of external beam irradiation and radioimmunotherapy in renal cell carcinoma xenografts. Int J Radiat Oncol Biol Phys 1989; 17: 125763.
  • 10
    Hall EJ, Brenner DJ. The dose-rate effect revisited: radiobiological considerations of importance in radiotherapy. Int J Radiat Oncol Biol Phys 1991; 21: 140314.
  • 11
    Press OW, Eary JF, Appelbaum FR, Martin PJ, Nelp WB, Glenn S, et al. Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 1995; 346: 33640.
  • 12
    DeNardo GL, DeNardo SJ, O'Grady LF, Levy NB, Adams GP, Mills SL. Fractionated radioimmunotherapy of B-cell malignancies with 131I- Lym-1. Cancer Res 1990; 50(Suppl): 10146.
  • 13
    DeNardo GL, DeNardo SJ, Lamborn KR, Goldstein DS, Levy NB, Lewis JP, et al. Low-dose fractionated radioimmunotherapy for B-cell malignancies using 131I-Lym-1 antibody. Cancer Biother Radiopharm 1998; 13: 23954.
  • 14
    DeNardo GL, DeNardo SJ, Goldstein DS, Kroger LA, Lamborn KR, Levy NB, et al. Maximum tolerated dose, toxicity, and efficacy of 131I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. J Clin Oncol 1998; 16: 324656.
  • 15
    Richman CM, DeNardo SJ, O'Grady LF, DeNardo GL. Radioimmunotherapy for breast cancer using escalating fractionated doses of 131I-labeled chimeric L6 antibody with peripheral blood progenitor cell transfusions. Cancer Res 1995; 55(Suppl): 591620.
  • 16
    DeNardo SJ, DeNardo GL, O'Grady LF, et al. Radioimmunotherapy of lymphoma with fractionated I-131 Lym-1: Phase I/II study [abstract]. J Nucl Med 1987; 28: 1077.
  • 17
    Jain RK. Vascular and interstitial barriers to delivery of therapeutic agents in tumors. Cancer Metastasis Rev 1990; 9: 25366.
  • 18
    Humm JL. Dosimetric aspects of radiolabeled antibodies for tumor therapy. J Nucl Med 1986; 27: 14907.
  • 19
    Fujimori K, Covell DG, Fletcher JE, Weinstein JN. Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab′)2, and Fab in tumors. Cancer Res 1989; 49: 565663.
  • 20
    Van Osdol W, Fujimori K, Weinstein JN. An analysis of monoclonal antibody distribution in microscopic tumor nodules: consequences of a “binding site barrier.” Cancer Res 1991; 51: 477684.
  • 21
    Baxter LT, Yuan F, Jain RK. Pharmacokinetic analysis of the perivascular distribution of bifunctional antibodies and haptens: comparison with experimental data. Cancer Res 1992; 52: 583844.
  • 22
    Buchsbaum DJ, Wessels BW. Introduction: radiolabeled antibody tumor dosimetry. Med Phys 1993; 20: 499501.
  • 23
    Roberson PL, Buchsbaum DJ. Reconciliation of tumor dose response to external beam radiotherapy versus radioimmunotherapy with 131Iodine-labeled antibody for colon cancer model. Cancer Res 1995; 55(Suppl): 5811s6s.
  • 24
    O'Donoghue JA. The implications of nonuniform tumor doses for radioimmunotherapy. J Nucl Med 1999; 40: 133741.
  • 25
    Meredith RF, Buchsbaum DJ, Knox SJ. Radioimmunotherapy. In: Gunderson L, Tepper J, editors. Clinical radiation oncology. New York: Churchill Livingstone, 2000; 28399.
  • 26
    Jain RK. Determinants of tumor blood flow: a review. Cancer Res 1988; 48: 264158.
  • 27
    Weinstein JN, van Osdol W. The macroscopic and microscopic pharmacology of monoclonal antibodies. Int J Immunopharmacol 1992; 14: 45763.
  • 28
    Dvorak HF, Nagy JA, Feng D, Dvorak AM. Tumor architecture and targeted delivery. In: Abrams PG, Fritzberg AR., editors. Radioimmunotherapy of cancer. New York: Marcel Dekker, 2000: 10735.
  • 29
    Eskey CJ, Koretsky AP, Domach MM, Jain RK. 2H-nuclear magnetic resonance imaging of tumor blood flow: spacial and temporal heterogeneity in a tissue-isolated mammary adenocarcinoma. Cancer Res 1992; 52: 60109.
  • 30
    Weidner N, Folkman J. Tumoral vascularity as a prognostic factor in cancer. In: DeVita VT, Hellman S, Rosenberg SA., editors. Important advances in oncology. Philadelphia: Lippincott, 1996: 16790.
  • 31
    Shockley TR, Lin K, Nagy JA, Tompkins RG, Yarmush ML, Dvorak HF. Spatial distribution of tumor-specific monoclonal antibodies in human melanoma xenografts. Cancer Res 1992; 52: 36776.
  • 32
    Lin K, Nagy JA, Xu H, Shockley TR, Yarmush ML, Dvorak HF. Compartmental distribution of tumor-specific monoclonal antibodies in human melanoma xenografts. Cancer Res 1994; 54: 226977.
  • 33
    Brown RS, Kaminski MS, Fisher SJ, Chang AE, Wahl RL. Intratumoral microdistribution of [131I]MB-1 in patients with B-cell lymphoma following radioimmunotherapy. Nucl Med Biol 1997; 24: 65763.
  • 34
    Jain RK, Baxter LT. Mechanisms of heterogenious distibution of monoclonal antibpdies and other macromolecules in turmors; significance of elevated interstitial pressure [abstract]. Cancer Res 1988; 48: 7022.
  • 35
    Netti PA, Baxter LT, Boucher Y, Skalak R, Jain RK. Time-dependent behavior of interstitial fluid pressure in solid tumors: implications for drug delivery. Cancer Res 1995; 55: 54518.
  • 36
    Stohrer M, Boucher Y, Stangassinger M, Jain RK. Oncotic pressure in solid tumors is elevated. Cancer Res 2000; 60: 42515.
  • 37
    Boucher Y, Jain RK. Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: implications for vascular collapse. Cancer Res 1992; 52: 51104.
  • 38
    Boucher Y, Leunig M, Jain RK. Tumor angiogenesis and interstitial hypertension. Cancer Res 1996; 56: 42646.
  • 39
    Fujimori K, Covell DG, Fletcher JE, Weinstein JN. A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier. J Nucl Med 1990; 31: 11918.
  • 40
    Juweid M, Neumann R, Paik C, Perez-Bacete MJ, Sato J, van Osdol W,et al. Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. Cancer Res 1992; 52: 514453.
  • 41
    Saga T, Neumann R, Heya T, Sato J, Kinuya S, Le N, et al. Targeting cancer micrometastases with monoclonal antibodies: a binding-site barrier. Proc Natl Acad Sci 1995;92: 89999003.
  • 42
    Griffith MH, Yorke ED, Wessels BW, DeNardo GL, Neacy WP. Direct dose confirmation of quantitative autoradiography with micro-TLD measurements for radioimmunotherapy. J Nucl Med 1988; 29: 1795809.
  • 43
    Buchsbaum DJ, Brubaker PG, Hanna DE, Glatfelter AA, Terry VH, Guilbault DM, et al. Comparative binding and preclinical localization and therapy studies with radiolabeled human chimeric and murine 17-1A monoclonal antibodies. Cancer Res 1990; 50: 9939.
  • 44
    Buchsbaum DJ, ten Haken RK, Heidorn DB, Lawrence TS, Glatfelter AA, Terry VH, et al. A comparison of 131I-labeled monoclonal antibody 17-1A treatment to external beam irradiation on the growth of LS174T human colon carcinoma xenografts. Int J Radiat Oncol Biol Phys 1990; 18: 103341.
  • 45
    Schlom J, Molinolo A, Simpson JF, Siler K, Roselli M, Hinkle G, et al. Advantage of dose fractionation in monoclonal antibody-targeted radioimmunotherapy. J Natl Cancer Inst 1990; 82: 76371.
  • 46
    Buchsbaum DJ, Khazaeli MB, Liu TP, Bright S. Fractionated radioimmunotherapy of human colon carcinoma xenografts with I-131-labeled monoclonal antibody CC49. Cancer Res 1995; 55(Suppl): 58817.
  • 47
    Anderson CJ, Jones LA, Bass LA, Sherman ELC, McCarthy DW, Cutler PD, et al. Radiotherapy, toxicity and dosimetry of copper-64-TETA-octreotide in tumor-bearing rats. J Nucl Med 1998; 39: 194451.
  • 48
    Vriesendorp HM, Quadri SM, Andersson BS, Dicke KA. Hematologic side effects of radiolabeled immunoglobulin therapy. Exp Hematol 1996; 24: 118390.
  • 49
    Blumenthal RD, Alisauskas R, Lew W, Sharkey RM, Goldenberg DM. Myelosuppressive changes from single or repeated doses of radioantibody therapy: effect of bone marrow transplantation, cytokines, and hematopoietic suppression. Exp Hematol 1998; 26: 85968.
  • 50
    O'Donoghue JA. Dosimetric aspects of radioimmunotherapy. Tumor Targeting 1998; 3: 10511.
  • 51
    Ruan S, O'Donoghue JA, Larson SM, Finn RD, Jungbluth A, Welt S, et al. Optimizing the sequence of combination therapy with radiolabeled antibodies and fractionated external beam. J Nucl Med 2000; 41: 190512.
  • 52
    Vriesendorp HM, Shao Y, Blum JE, Quadri SM, Williams JR. Fractionated intravenous administration of 90Y-labeled B72.3 GYK-DTPA immunoconjugate in beagle dogs. Nucl Med Biol 1993;20: 5718.
  • 53
    Esteban JM, Schlom J, Mornex F, et al. Radioimmunotherapy of athymic mice bearing human colon carcinomas with monoclonal antibody B72.3: histological and autoradiographic study of effects on tumors and normal organs. Eur J Cancer Clin Oncol 1987;23: 64355.
  • 54
    Buchsbaum DJ, Khazaeli MB, Mayo MS, Roberson PL. Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model. Clin Cancer Res 1999; 5: 3153s3159s.
  • 55
    Roberson PL, Dudek S, Buchsbaum DJ. Dosimetric comparison of bolus and continuous injections of CC49 monoclonal antibody in a colon cancer xenograft model. Cancer 1997; 80: 256775.
  • 56
    Beaumier PL, Venkatesan P, Vanderheyden JL, Burgua WD, Kunz LL, Fritzberg AR, et al. 186-Re radioimmunotherapy of small cell lung carcinoma xenografts in nude mice. Cancer Res 1991; 51: 67681.
  • 57
    Blumenthal RD, Sharkey RM, Kashi R, Goldenberg DM. Suppression of tumor vascular activity by radioantibody therapy: Implications for multiple cycle treatments. Sel Cancer Ther 1991; 7: 916.
  • 58
    Blumenthal RD, Kashi R, Sharkey RM, Goldenberg DM. Quantitative and qualitative effects of experimental radioimmunotherapy on tumor vascular permeability. Int J Cancer 1995; 61: 55766.
  • 59
    Blumenthal RD, Sharkey RM, Kashi R, Sides K, Stein R, Goldenberg DM. Changes in tumor vascular permeability in response to experimental radioimmunotherapy: a comparative study of 11 xenografts. Tumor Biol 1997; 18: 36777.
  • 60
    Meredith RF, Khazaeli MB, Liu T, Plott G, Wheeler RH, Russel C, et al. Dose fractionation of radiolabeled antibodies in patients with metastatic colon cancer. J Nucl Med 1992; 33: 164853.
  • 61
    Meredith RF, Khazaeli MB, Plott WE, Liu T, Russell CD, Wheeler RH, et al. Effect of human immune response on repeat courses of 131I-chimeric B72.3 antibody therapy. Antibody Immunoconj Radiopharm 1993;6: 3946.
  • 62
    Press OW, Eary JF, Appelbaum FR, Martin PJ, Badger CC, Nelp WB, et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993; 329: 121924.
  • 63
    Epstein AL, Marder RJ, Winter JN, Stathopoulos E, Chen FM, Parker JW, et al. Two new monoclonal antibodies, Lym-1 and Lym-2, reactive with human-B-lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential. Cancer Res 1987; 47: 83040.
  • 64
    Divgi CR, O'Donoghue JA, McGagh DA, et al. Fractionated radioimmunotherapy with I-131-labeled chimeric antibody G250 (CG250) in patients with metastatic renal cell carcinoma [Abstract 970]. J Nucl Med 1999; 40(5 suppl):217P.
  • 65
    Vriesendorp HM, Quadri SM, Wyllie CT, Lai J, Borchardt PE, Harris L, et al. Fractionated radiolabeled antiferritin therapy for patients with recurrent Hodgkin's disease. Clin Cancer Res 1999; 5: 33249.
  • 66
    Vriesendorp HM, Quadri SM. Update: radiolabeled immunoglobulin therapy in patients with Hodgkin's disease. Cancer Biother Radiopharm 2000; 15: 43146.
  • 67
    Withers HR, Peters LJ, Thames HD, Fletcher GH. Responses of normal tissues to dose fractionation. Cancer Bull 1982; 34: 1825.
  • 68
    Dale RG. The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy. Br J Radiol 1985; 58: 51528.
  • 69
    Shen S, DeNardo GL, Jones TD, Wilder RB, O'Donnell RT, DeNardo SJ. A preliminary cell-kinetics model of thrombocytopenia after radioimmunotherapy [abstract]. J Nucl Med 1998; 39: 12239.
  • 70
    O'Donoghue JA. Dosimetric principles of targeted radiotherapy. In: Fritzberg A, Abrams P, editors. Radioimmunotherapy of cancer. New York: Marcel Dekker, 2000: 120.
  • 71
    Rao DV, Howell RW. Time-dose-fractionation in radioimmunotherapy: implications for selecting radionuclides. J Nucl Med 1993; 34: 180110.
  • 72
    Fowler JF. Radiobiological aspects of low dose rates in radioimmunotherapy. Int J Radiat Oncol Biol Phys 1990; 18: 12619.
  • 73
    Knox SJ, Sutherland W, Goris ML. Correlation of tumor sensitivity to low-dose-rate irradiation with G2/M-phase block and other radiobiological parameters. Radiat Res 1993; 135: 2431.
  • 74
    Moulder JE, Fish BL, Wilson JF. Tumor and normal tissue tolerance for fractionated low-dose-rate radiotherapy. Int J Radiat Oncol Biol Phys 1990; 19: 3418.
  • 75
    Barendsen GW. Dose fractionation, dose-rate and isoeffect relationships for normal tissue responses. Int J Radiat Oncol Biol Phys 1982; 8: 198197.
  • 76
    Withers HR, Thames HD, Peters LJ. A new isoeffect curve for changes in dose per fraction. Radiother Oncol 1983; 1: 18791.
  • 77
    Kellerer AM, Rossi HH. A generalised definition of dosimetric quantities. Int J Radiat Biol 1990; 57: 85964.
  • 78
    Bentzen SM, Johansen LV, Overgaard J, Thames HD. Clinical radiobiology of squamous cell carcinoma of the oropharynx. Int J Radiat Oncol Biol Phys 1991; 20: 1197206.
  • 79
    Maciejewski B, Majewski S. Dose fractionation and tumour repopulation in radiotherapy for bladder cancer. Radiother Oncol 1991; 21: 16370.
  • 80
    Fowler JF, Lindstrom MJ. Loss of local control with prolongation in radiotherapy. Int J Radiat Oncol Biol Phys 1992; 23: 45767.
  • 81
    Skladowski K, Law MG, Maciejewski B, Steel GG. Planned and unplanned gaps in radiotherapy: the importance of gap position and gap duration. Radiother Oncol 1994; 30: 10920.
  • 82
    Chappell R, Nondahl DM, Rezvani M, Fowler JF. Further analysis of radiobiological parameters from the first and second British-Institute-of-Radiology randomized studies of larynx pharynx radiotherapy. Int J Radiat Oncol Biol Phys 1995; 33: 50918.
  • 83
    Petereit DG, Sarkaria JN, Chappell R, Fowler JF, Hartmann TJ, Kinsella TJ, et al. The adverse effect of treatment prolongation in cervical carcinoma. Int J Radiat Oncol Biol Phys 1995; 32: 13017.
  • 84
    Withers HR, Taylor JM, Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 1988; 27: 13146.
  • 85
    Trott KR. Cell repopulation and overall treatment time. Int J Radiat Oncol Biol Phys 1990; 19: 10715.
  • 86
    Fowler JF. The phantom of tumor treatment-continually rapid proliferation unmasked. Radiother Oncol 1991; 22: 1568.
  • 87
    Bentzen SM, Saunders M, Dische S. Repair halftimes estimated from observations of treatment-related morbidity after CHART or conventional radiotherapy in head and neck cancer. Radiother Oncol 1999; 53: 21926.
  • 88
    O'Donoghue JA, Sgouros G, Divgi CR, Humm JL. Single-dose versus fractionated radioimmunotherapy: Model comparisons for uniform tumor dosimetry. J Nucl Med 2000; 41: 53847.
  • 89
    Sun LQ, Vogel CA, Mirimanoff RO, et al. Timing effects of combined radioimmunotherapy and radiotherapy on a human solid tumor in nude mice. Cancer Res 1997; 57: 13129.
  • 90
    Whitmore GF, Till JE, Gulyas S. Radiation-induced mitotic delay in L-cells. Radiat Res 1967; 30: 15571.
  • 91
    DeWeese TL, Shipman JM, Dillehay LE, Nelson WG. Sensitivity of human prostatic carcinoma cell lines to low dose rate radiation exposure. J Urol 1998; 159: 5918.
  • 92
    Williams JA, Williams JR, Yuan X, Dillehay LE. Protracted exposure radiosensitization of experimental human malignant glioma. Radiat Oncol Invest 1998; 6: 25563.
  • 93
    Oosterwijk E, Bander NH, Divgi CR, Welt S, Wakka JC, Finn RD, et al. Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250. J Clin Oncol 1993; 11: 73850.
  • 94
    Finstad CL, LLoyd KO, Federici MG, Divgi C, Venkatraman E, Barakat RR, et al. Distribution of radiolabeled monoclonal antibody MX35 F(ab′)2 in tissue samples by storage phosphor screen image analysis: evaluation of antibody localization to micrometastatic disease in epthelial ovarian cancer. Clin Cancer Res 1997; 3: 143342.
  • 95
    Steffens MG, Boerman OC, Oyen WJ, Kniest PH, Witjes JA, Oosterhof GO, et al. Intratumoral distribution of two consecutive injections of chimeric antibody G250 in primary renal cell carcinoma: implications for fractionated dose radioimmunotherapy. Cancer Res 1999; 59: 16159.
  • 96
    DeNardo GL, DeNardo SJ. Overview of obstacles and opportunities for radioimmunotherapy of cancer. In: Goldenberg DM, editor. Cancer therapy with radiolabeled antibodies. Boca Raton, Florida: CRC, 1994: 14154.
  • 97
    DeNardo GL, DeNardo SJ. Perspectives on the future of radioimmunodiagnosis and radioimmunotherapy of cancer. In: Burchiel SW, Rhodes BA., editors. Radioimmunoimaging and radioimmunotherapy. New York: Elsevier, 1983: 4162.
  • 98
    Jain RK. Haemodynamic and transport barriers to the treatment of solid tumors. Int J Radiat Biol 1991; 60: 85100.
  • 99
    Jain RK. Barriers to drug delivery in solid tumors. Sci Am 1994; 271: 5865.
  • 100
    Langmuir VK, McGann JK, Buchegger F, Sutherland RM. The effect of antigen concentration, antibody valency and size, and tumor architecture on antibody binding in multicell spheroids. Nucl Med Biol 1991; 18: 75364.
  • 101
    Otte A, Herrmann R, Heppeler A, Behe M, Jermann E, Powell P, et al. Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med 1999; 26: 143947.
  • 102
    Sinzinger H, Granegger S, Meghdadi S, Kratzik C. Pain palliation with 153Sm-EDTMP using the Vienna protocol [abstract]. Eur J Nucl Med 2000; 27: 965.
  • 103
    Iwahashi M, Milenic DE, Padlan EA, Bei R, Schlom J, Kashmiri SVS. CDR substitutions of a humanized monoclonal antibody (CC49): contributions of individual CDRs to antigen binding and immunogenicity. Mol Immunol 1999; 36: 107991.
  • 104
    Tamura M, Milenic DE, Iwahashi M, Padlan EA, Schlom J, Kashmiri SVS. Structural correlates of an anticarcinoma Ab: identification of specificity-determining residues (SDRs) and development of a minimally immunogenic antibody variant by retention of SDRs only. J Immunol 2000; 16: 143241.
  • 105
    Yokota T, Milenic D, Whitlow M, Schlom J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 1992; 52: 34028.
  • 106
    Nias AHW. Fractionated radiotherapy. In: Nias AHW, editor. An Introduction to Radiobiology. Chichester, England: John Wiley & Sons, 1990: 25676.
  • 107
    Meyn RE. Apoptosis and response to radiation: implications for radiation therapy. Oncology 1997; 11: 34956.
  • 108
    Buchegger F, Vacca A, Carrel S, Schreyer M, Mach JP. Radioimmunotherapy of human colon carcinoma by 131I-labelled monoclonal anti-CEA antibodies in a nude mouse model. Int J Cancer 1988; 41: 12734.